Quintara Biosciences offers customized LNP encapsulation services to support the identification of high-efficiency, low-toxicity and stable delivery systems. The platform supports preclinical in vitro and in vivo studies with flexible lipid options, scalable production and phase-appropriate testing for mRNA and saRNA payloads, accelerating the development of innovative nucleic acid therapeutics.
Launch Promotion
Offer:
IVT mRNA Synthesis & LNP Encapsulation Bundle
• Research Grade: 10% OFF
• Preclinical Grade: 15% OFF
Terms and Conditions:
• The promotional pricing applies to all qualifying LNP Encapsulation Service orders and is available to all customers.
• Contact sales.us@quintarabio.com for your personalized quote and discount.
• Quintara Biosciences reserves all rights to this promotion.
The existing platform combines lipid nanoparticle encapsulation, flexible formulation options, scalable production and an integrated path from gene synthesis to mRNA-LNP products.
High encapsulation efficiency
Reduced immunogenicity and toxicity
High delivery efficiency of mRNA
Validated commercial lipids
Recommended formulations with clear IP ownership
Client-supplied lipids
Preclinical grade: Batches up to 1000 mL
Seamless transition from preclinical research to clinical-stage development
Integrated solutions: From gene synthesis to delivery-ready mRNA-LNP products
Rapid turnaround: As fast as 4 weeks starting from CDS sequence
LNP encapsulation is the process of incorporating a nucleic acid payload, such as mRNA or saRNA, into lipid nanoparticles to create a formulation. The lipid nanoparticle helps package the RNA payload into a controlled particle system for subsequent in vitro or in vivo research.
A typical lipid nanoparticle formulation combines the selected RNA payload with appropriate lipid components under controlled formulation conditions. The resulting mRNA-LNP formulation is then evaluated for key quality attributes such as encapsulation efficiency, particle size, polydispersity index, concentration, integrity and endotoxin level.
Quintara Biosciences provides customized LNP encapsulation services with multiple lipid and formulation options. Customers may select validated commercial lipids, recommended formulations with clear IP ownership or client-supplied lipids according to their project requirements. The service supports both Research Grade and Preclinical Grade mRNA and saRNA encapsulation.
The LNP formulation process connects gene synthesis, plasmid preparation and mRNA synthesis with LNP preparation and strict quality control. This coordinated workflow supports mRNA-LNP formulation from the starting CDS sequence through mRNA-LNP product.
Fast turnaround
Highest level of accuracy
Free-to-operate plasmid backbone available
Validated UTR sequences
Stable Poly (A) tail
dsRNA reduced synthesis options
Non-infringing cap analogs and enzyme options
Purification options for various applications
Load from 0.5 mg to 100 mg of mRNA
Multiple lipid and formulation options
High encapsulation efficiency
Comprehensive testing panels
Additional testing options available
Standard Report of Analysis (RoA) provided
Quintara Biosciences offers Research Grade and Preclinical Grade LNP formulation options that support mRNA-LNP encapsulation projects with clearly defined payload scales, turnaround times, deliverables and phase-appropriate testing.
Research Grade | Preclinical Grade | |
Payload* | mRNA, saRNA | mRNA, saRNA |
Scale | 0.5 - 5mg | 10 -100 mg |
| Turnaround Time | 5-7 Business days | 7-9 Business days |
Deliverables | a)Individual cryotubes b)RoA | a)Individual cryotubes b)RoA |
* Additional payload types available upon request.
| Item | Method | Standard | Research Grade | Preclinical Grade |
| Appearance | Visual inspect | Clear and free of foreign particles |  | |
Concentration | RiboGreen | 0.05 – 0.4 mg/mL | | |
Encapsulation Efficiency | RiboGreen | > 85% | | |
Integrity | Capillary Electrophoresis | <4k nt: ≥75% >4k nt: report value |  | |
Particle Size | DLS | MC3-LNP 80-110 nm | | |
SM102-LNP 65-125 nm | ||||
LP01-LNP 65-125 nm | ||||
ALC0315-LNP 50-100 nm | ||||
DHA-1-LNP 50-100 nm | ||||
Lipid 5-LNP 65-125 nm | ||||
Novel lipid: report value | ||||
PDI | DLS | Commercial lipids< 0.2 | | |
Zeta Potential | Zetasizer | ± 20.0 mV | | |
pH | pH Meter | 7.4 ± 0.5 | | |
| Endotoxin | Semiquantitative | <10EU/mg | | |
| Bioburden | Direct inoculation | No growth after 72 hrs | |  |
* ×: Not Included √: Included +: Optional
| Product | Catalog No. | Price |
| eGFP mRNA (m1Ψ) 0.2 mg | QPM90001-M | $315.00 |
| eGFP mRNA (m1Ψ) 1 mg | QPM90001-L | $1,170.00 |
| Product | Catalog No. | Price |
| Fluc mRNA (m1Ψ) 0.2 mg | QPM90002-M | $315.00 |
| Fluc mRNA (m1Ψ) 1 mg | QPM90002-L | $1,170.00 |
Precision and custom gene synthesis from Quintara Biosciences for your research needs.
Discover more
High-quality plasmid DNA with 100% full-sequence accuracy and guaranteed yield.
Discover more
Quintara delivers fast, affordable NGS sequencing using advanced platforms.
Discover more
We Go Fast, You Go Forward
sales.us@quintarabio.com
1-617-789-6111
3563 Investment Blvd, #2, Hayward, CA 94545sales.us@quintarabio.com1-617-789-611165 Grove St, Suite 102, Watertown, MA 02472sales.us@quintarabio.com1-346-239-997110410 Corporate Dr. Suite 118, Sugar Land, TX 77478sales.us@quintarabio.com
1-424-549-091110601 Virginia Avenue, Culver City, CA 90232sales.us@quintarabio.com1-619-823-08956364 Ferris Square, Suite 102, San Diego, CA 92121Quintara Biosciences © 2025 All Rights Reserved | Site Map | Terms of Use | Privacy Policy
Login 
Order
Contact Us
Contact Us
